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It is a well established fact that the incidence of sun-related skin 
damage (photo-ageing) and neoplastic 
transformation (photo-carcinogenesis) 
has progressively increased in recent 
decades as a result of cultural and 
occupational trends leading to 
increased sun exposure and use of 
sunbeds, particularly in Caucasian 
populations. 
Consequences of chronic sun-
damage include actinic (solar) keratosis 
(AK), basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC). AK 
presents as a scaly keratotic plaque 
which varies in thickness from thin 
to hypertrophic (including keratin 
horn). AKs are considered to be 
mildly pre-malignant, and the rate 
of transformation to invasive SCC is 
thought to be less than 1%. In fact 
most SCCs develop within a pre-
existing AK. The in-situ pre-invasive 
form of SCC is known as intra-epithelial 
carcinoma or Bowen’s disease. 
Clinically, this can sometimes look 
similar to superficial BCC. It typically 
presents as a flat scaly plaque on 
an erythematous background, rather 
like a psoriasiform plaque. It is most 
commonly found on the extremities, but 
sometimes also on the head, neck and 
trunk. The commonest clinical variants 
of BCC are nodular BCC and superficial 
BCC. Superficial BCC typically presents 
on the trunk or extremities as flat pink/
red annular lesion often with some 
scale and a subtle raised translucent 
edge. It may also contain some 
pigment. Another name for superficial 
BCC is multi-centric BCC.
Apart from the common UV-related 
aetiology, AK, superficial BCC and 
Bowen’s disease, have one other thing 
in common. They exhibit an excellent 
response rate to treatment with a 
topical immune response modulator 
known as Imiquimod (Aldara™). For 
AKs to respond to imquimod they 
must not be hypertrophic. Indeed, 
this product which comes as a 5% 
cream is licensed for treating these 
3 types of lesions, apart from genital 
warts. Traditional treatments include: 
cryotherapy, curettage and cautery 
(C&C), topical 5-fluorouracil, and lately, 
photo-dynamic therapy (PDT) for AK; 
cryotherapy, C&C, excision, topical 
5-fluorouracil, radiotherapy and PDT 
for superficial BCC; cryotherapy, C&C, 
excision, topical 5-fluorouracil and PDT 
for Bowen’s disease.
Imiquimod acts through toll-like 
receptors, predominantly expressed 
on dendritic cells and monocytes, to 
induce production of cytokines and 
chemokines which promote both innate 
and adaptive cell-mediated immune 
response against the dysplastic/
neolastic cells. 
The recommended treatment 
regimes are: 5 times a week, Monday to 
Friday, for 6 weeks for superficial BCC; 
5 times a week, Monday to Friday, for 
6-12 weeks for Bowen’s disease. For 
AK, it should be used three times per 
week on alternate days (Mon-Wed-Fri) 
for 4 weeks. After a 4 week treatment-
free period lesions should be assessed 
and if any lesions persist treatment 
can be repeated for another 4 weeks. 
Maximum duration of treatment is 8 
weeks.
A box of Imiquimod contains 12 
packets, each containing 12.5mg of 
cream.  The cream should be applied 
as a thin layer to the target area at 
bedtime and washed off with mild 
soap and water the following morning. 
Contact with the eyes, lips and nostrils 
should be avoided, and hands washed 
before and after application. No more 
than one packet should be used 
at each application. Partially used 
packets should not be saved or reused. 
Local skin inflammatory reactions are 
common. Flu-like symptoms such 
as malaise, fever, nausea, myalgias 
and rigors may also occasionally 
accompany local reactions. Patients 
should be forewarned about the 
possibility of these reactions. A rest 
period of several days may be taken if 
patients cannot tolerate the intensity of 
the reaction. The safety of imiquimod 
cream applied to areas of skin greater 
than 25cm2 for treatment of AKs has 
not been established, and hence should 
be avoided. Exposure to sunlight 
should be avoided or minimized during 
use of imiquimod cream because of the 
possibility of increased susceptibility 
to sunburn. The safety of imiquimod in 
pregnancy and nursing mothers has not 
been established, and hence caution 
should be exercised in these situations.
Topical imiquimod represents 
a novel highly effective patient-
administered treatment for non-
hypertrophic AKs, superficial BCCs 
and Bowen’s disease. In view of the 
high incidence of adverse reactions 
to this agent, prescribers must pay 
particular attention to appropriate 
patient selection and should take time 
to thoroughly explain the treatment 
regime and common side-effects during 
the initial consultation. 
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